摘要
目的观察依达拉奉治疗急性脑梗死的疗效及其安全性。方法将100例急性脑梗死患者随机分为观察组和对照组,各50例。对照组给予神经内科常规治疗,观察组在对照组基础上加用依达拉奉治疗。结果观察组治疗后的NIHSS评分明显低于对照组,而ADL评分明显增高,差异均有统计学意义(P<0.01)。观察组的临床疗效明显优于对照组(P<0.05)。两组均未出现严重不良事件。结论依达拉奉能够有效改善急性脑梗死患者的神经功能缺损和恢复其日常生活能力,有效地防止患者的脑水肿发生,增强其疗效。
Objective To observe the efficacy and safety of edaravone in the treatment of a- cute cerebral infarction. Methods A total of 100 patients with acute cerebral infarction were ran- domly divided into observation group （ n = 50） and control group （ n = 50）. Both groups received conventional treatment. But the observation group received additional edaravone. Results After treatment, NIHSS score of the observation group was significantly lower than that of the control group and the ADL score significantly higher. Therefore, there were significant differences （P 〈 0. 01 ）. The clinical efficacy of the observation group was much better than the control group （P 〈 0. 05）. Both groups had no serious adverse events. Conclusion To the patients with acute cerebral in- farction, edaravone can effectively improve their neurologic impairment, restore the ability of their daily life, prevent their brain edema, and enhance the curative effect.
出处
《实用临床医药杂志》
CAS
2012年第19期107-109,共3页
Journal of Clinical Medicine in Practice
关键词
急性脑梗死
依达拉奉
自由基清除剂
acute cerebral infarction
edaravone
free radical scavenger
